Open Forum Infectious Diseases · 2025 · 11 citations · 26 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntibiotic ResistanceEmpiric Antimicrobial TherapyAntimicrobial Prescribing Pattern AnalysisCarbapenem-resistant EnterobacteralesEnterobacterales ResistanceGram-negative Bacterial InfectionsObservational Study EvaluationPseudomonas Aeruginosa Infection TreatmentPseudomonas Aeruginosa Resistanceβ-Lactam Antibiotics
Abstract Background Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. This study aims to describe the patient characteristics, prescribing patterns, and clinical outcomes associated with IMI/REL. Methods This was a retrospective, multicenter, observational study of patients ≥18 years old who received IMI/REL for ≥48 hours for a suspected or confirmed gram-negative infection. The primary outcome was clinical success, defined as improvement or resolution of infection-related signs or symptoms while receiving IMI/REL and the absence of 30-day microbiologic failure. Multivariable logistic regression analysis was performed to identify independent predictors of clinical success. Results The study included 151 patients from 24 US medical centers. IMI/REL was predominantly prescribed for lower respiratory tract infections, accounting for 52.3% of cases. Most patients were infected with a carbapenem-nonsusceptible pathogen (85.4%); P aeruginosa was frequently targeted (72.2%). Clinical success was achieved in 70.2% of patients. Heart failure, receipt of antibiotics within the past 90 days, intensive care unit admission at time of index culture collection, and isolation of difficult-to-treat resistant P aeruginosa were independently associated with a reduced odds of clinical success. Adverse events were reported in 6.0% of patients, leading to discontinuation of IMI/REL in 3 instances. Conclusions This study provides a comprehensive analysis of the real-world effectiveness and safety of IMI/REL. Comparative studies and investigations of specific subgroups will further enhance our understanding of IMI/REL in treating MDR infections.
26
Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 51.7K citations · Full text
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey et al. · Clinical Microbiology and Infection · 2011 · 14K citations
William A. Knaus, Elizabeth A. Draper, Douglas P. Wagner et al. · Critical Care Medicine · 1985 · 13.7K citations
Medicine, Internal Medicine, Clinical Classification Systems +16
APACHE II: a severity of disease classification system.
Elizabeth S. Draper · PubMed · 1985 · 6.1K citations